The Effect of Brief Potent Glutamatergic Modulation on Disordered Alcohol Use
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group
研究概览
简要总结
Alcohol use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered drinking. Alcohol use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) for alcohol use disorders.
详细描述
Individuals diagnosed with alcohol dependence will be randomized to receive a single infusion of glutamate modulators during week 2 while engaged in a 5-week course of MET. They will meet with staff twice weekly, except for week 2 during which they will present to the clinic three times. Clinic visits include MET sessions, psychiatric monitoring, assessments, and study procedures (e.g., medication administration).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 69 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Active alcohol dependence. In the case of the use of other drugs, alcohol is designated as the primary drug. At least four heavy drinking day over the past 7 days (>4 drinks a day for males, >3 drinks for females) OR minimum weekly use of 35 drinks for males and 28 for females
- •Physically healthy
- •No adverse reactions to study medications
- •21-69 years of age
- •Capacity to consent and comply with study procedures, including sufficient proficiency in English
- •Seeking to reduce or stop alcohol use
排除标准
- •Meets criteria for current major depression, bipolar disorder, schizophrenia, any psychotic illness, including substance induced psychosis, and current substance-induced mood disorder.
- •Physiological dependence on another substance requiring medical management, such as opiods or benzodiazepines, excluding caffeine, nicotine, and cannabis
- •Delirium, Dementia, Amnesia, Cognitive Disorders, or Dissociative disorders. Significant dissociative symptoms
- •Current suicide risk or a history of suicide attempt within the past year
- •Inability to safely initiate 24 hours of abstinence from alcohol; repeated inability to initiate abstinence during the trial without incurring significant withdrawal; history of severe withdrawal phenomena over the past 6 months (e.g., withdrawal-related seizure); or self-reported inability to maintain abstinence for 24 hours without substantial distress.
- •Pregnant or interested in becoming pregnant during the study period
- •Any of the following cardiac conditions: clinically significant left ventricular hypertrophy, angina, clinically significant arrhythmia, or mitral valve prolapse
- •Unstable physical disorders which might make participation hazardous such as end-stage AIDS, hypertension (>140/90), leukopenia, active hepatitis or other liver disease with elevated transaminase levels (< 2-3 X upper limit of normal will be considered acceptable if clotting factors are normal), renal failure, epilepsy, or untreated diabetes
- •Previous history of study medication misuse or abuse, and a history of an adverse reaction/experience with prior exposure to study medications
- •Recent history of significant violence (past 2 years)
- •First degree relative with a psychotic disorder (bipolar disorder, schizophrenia, schizoaffective disorder, or psychosis NOS)
- •On psychotropic or other medications whose effect could be disrupted by participation in the study
- •BMI > 35
研究组 & 干预措施
CI-581a+MET
Administration of CI-581a during wk 2 at 0.71 mg/kg in the context of a 5 wk course of MET
干预措施: CI-581a (Drug)
CI-581a+MET
Administration of CI-581a during wk 2 at 0.71 mg/kg in the context of a 5 wk course of MET
干预措施: Motivational Enhancement Therapy (MET) (Behavioral)
CI-581b+MET
Administration of CI-581b during wk 2 at 0.025 mg/kg in the context of a 5 wk course of MET
干预措施: CI-581b (Drug)
CI-581b+MET
Administration of CI-581b during wk 2 at 0.025 mg/kg in the context of a 5 wk course of MET
干预措施: Motivational Enhancement Therapy (MET) (Behavioral)
结局指标
主要结局
Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group
时间窗: 21 days post-infusion
Percentage of participants demonstrating alcohol abstinence in the control (midazolam) group versus the active (ketamine) group
次要结局
未报告次要终点
研究者
Elias Dakwar
Assistant Professor of Clinical Psychiatry
Columbia University